On May 08, 2014, Dendreon Corporation (NASDAQ:DNDN), reported results for the first quarter ended March 31, 2014. Net product revenue for the quarter was $68.8 million compared to $67.6 million in the first quarter of 2013. Dendreon Corporation (NASDAQ:DNDN), weekly performance is -22.40%. On last trading day company shares ended up $1.94. Analysts mean target price for the company is $3.20. Dendreon Corporation (NASDAQ:DNDN), distance from 50-day simple moving average (SMA50) is -31.12%.
On Amy 08, 2014, Depomed Inc (NASDAQ:DEPO), reported financial results for the first quarter ended March 31, 2014. Depomed Inc (NASDAQ:DEPO), shares fell 15.64% in last trading session and ended the day on $10.57. DEPO, Gross Margin is 94.70% and its return on assets is 18.50%. Depomed Inc (NASDAQ:DEPO), quarterly performance is -13.36%.
TheStreet Quant Ratings rates IsoRay, Inc. (NYSEMKT:ISR) as a sell. ISORAY INC has improved earnings per share by 33.3% in the most recent quarter compared to the same quarter a year ago. The net income growth from the same quarter one year ago has exceeded that of the Biotechnology industry average, but is less than that of the S&P 500. The net income increased by 19.7% when compared to the same quarter one year prior, going from -$1.16 million to -$0.93 million. IsoRay, Inc. (NYSEMKT:ISR), shares moved down 8.73% in last trading session and was closed at $2.30, while trading in range of $ 2.25 – 2.52. IsoRay, Inc. (NYSEMKT:ISR), year to date (YTD) performance is 360.00%.
Insys Therapeutics Inc (NASDAQ:INSY), announced that the company will present at the 2014 UBS Global Healthcare Conference on May 19-21, 2014 at the Sheraton New York Times Square Hotel in New York City. Insys Therapeutics Inc (NASDAQ:INSY), ended the last trading day at $32.68. Company weekly volatility is calculated as 11.31% and price to cash ratio as 24.61. Insys Therapeutics Inc (NASDAQ:INSY), showed a negative weekly performance of 19.01%.
Leave a Reply